Human placenta-derived mesenchymal stem cell administration protects against acute lung injury in a mouse model

J Cell Biochem. 2023 Sep;124(9):1249-1258. doi: 10.1002/jcb.30445. Epub 2023 Jul 14.

Abstract

This study aims to investigate the effect of placenta-derived mesenchymal stem cells (PMSCs) administration on tissue repair following acute lung injury (ALI). PMSCs were transplanted intravenously to a mouse model of lipopolysaccharide-induced ALI. The therapeutic effects were determined by evaluating several indicators, including pathology; the wet/dry ratio of the lungs; blood gas analysis; the total protein content, cell numbers, and the activity of myeloperoxidase (MPO) in bronchial alveolar lavage fluid (BALF); and the levels of anti-inflammatory and proinflammatory cytokines in serum and BALF. To investigate the underlying mechanism, PMSC-derived exosomes were used for ALI treatment. Administration of PMSCs improved the degree of lung injury, reduced inflammation, increased the expression levels of anti-inflammatory cytokines, and protected lung function. As expected, the effects of PMSC-derived exosomes in the ALI model were similar to those of PMSCs, both in terms of improved lung function and reduced inflammation. These findings suggest that PMSCs have ameliorating effects on ALI that are potentially mediated via their secreted exosomes.

Keywords: acute lung injury; anti-inflammatory; exosome; lipopolysaccharides; placenta-derived mesenchymal stem cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury* / chemically induced
  • Acute Lung Injury* / metabolism
  • Acute Lung Injury* / therapy
  • Animals
  • Cytokines / metabolism
  • Humans
  • Immunologic Factors
  • Inflammation / metabolism
  • Lipopolysaccharides / adverse effects
  • Lung / metabolism
  • Mesenchymal Stem Cells* / metabolism
  • Mice

Substances

  • Cytokines
  • Lipopolysaccharides
  • Immunologic Factors